Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at Chardan Capital

Tenaya Therapeutics (NASDAQ:TNYA)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $18.00 price target on the stock.

Several other equities analysts have also recently issued reports on TNYA. Leerink Partners reiterated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a report on Monday, November 25th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tenaya Therapeutics currently has an average rating of “Buy” and a consensus target price of $17.33.

Tenaya Therapeutics Stock Up 14.6 %

TNYA stock opened at $1.41 on Wednesday. The company has a 50-day simple moving average of $2.43 and a 200 day simple moving average of $2.71. The company has a market capitalization of $111.70 million, a P/E ratio of -0.98 and a beta of 2.72. Tenaya Therapeutics has a fifty-two week low of $0.99 and a fifty-two week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.07. Equities analysts anticipate that Tenaya Therapeutics will post -1.35 EPS for the current year.

Institutional Investors Weigh In On Tenaya Therapeutics

Several hedge funds have recently modified their holdings of the stock. Integral Health Asset Management LLC increased its stake in Tenaya Therapeutics by 3.3% in the 2nd quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock worth $7,208,000 after purchasing an additional 75,000 shares in the last quarter. FMR LLC increased its position in shares of Tenaya Therapeutics by 1.9% in the third quarter. FMR LLC now owns 1,345,938 shares of the company’s stock worth $2,598,000 after acquiring an additional 25,503 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Tenaya Therapeutics by 5.4% in the third quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock worth $2,502,000 after acquiring an additional 66,968 shares in the last quarter. State Street Corp raised its holdings in shares of Tenaya Therapeutics by 0.9% during the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock valued at $2,044,000 after acquiring an additional 9,506 shares during the period. Finally, abrdn plc purchased a new stake in shares of Tenaya Therapeutics in the 3rd quarter valued at approximately $1,063,000. 90.54% of the stock is owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.